Real-World data reveals how ibrance works in advanced breast cancer patients
NCT ID NCT06962969
First seen Apr 08, 2026 · Last updated May 23, 2026 · Updated 10 times
Summary
This study used a large database to observe the safety and effectiveness of the drug Ibrance (palbociclib) in adult women with advanced or metastatic breast cancer. Researchers looked at side effects and how well the treatment worked in real-world settings, outside of a clinical trial. The goal was to better understand the risks and benefits of this medication in everyday practice.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED OR METASTATIC BREAST CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Pfizer New York
New York, New York, 10001, United States
Conditions
Explore the condition pages connected to this study.